Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Eloxx Pharmaceuticals, Inc. (ELOX)
|
Add to portfolio |
|
|
|
| Price: |
$0.68
| | Metrics |
| OS: |
2.75
|
M
| |
|
|
| Market cap: |
$1.88
|
M
| |
|
|
|
Net debt:
|
$1.28
|
M
| |
|
|
|
EV:
|
$3.16
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($22.1)
|
M
| |
|
|
|
EBIT
|
($22.1)
|
M
| |
|
|
| EPS |
($7.84)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Jun-30-17 | Dec-31-16 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | | | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.6 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.6 | 0.0 |
| Gross margin | | | | | | | | |
| Research and development | 23.7 | 22.9 | 14.6 | 26.3 | 20.5 | 16.4 | 0.7 | 9.0 |
| General and administrative | 10.7 | 20.4 | 14.8 | 24.2 | 26.5 | 2.7 | 1.4 | 0.9 |
| EBIT | -34.4 | -43.3 | -29.4 | -50.6 | -47.6 | -20.4 | -4.7 | -9.8 |
| EBIT margin | | | | | | | | |
| Pre-tax income | -36.1 | -66.7 | -34.6 | -50.9 | -47.1 | -21.2 | -6.8 | -9.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | -1.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | 0.0% | 15.2% | 0.0% |
| Net income | -36.1 | -66.7 | -34.6 | -50.9 | -47.2 | -23.6 | -6.2 | -10.9 |
| Net margin | | | | | | | | |
| |
| Diluted EPS | ($16.65) | ($38.15) | ($0.86) | ($1.34) | ($1.45) | ($4.75) | ($0.27) | ($2.60) |
| Shares outstanding (diluted) | 2.2 | 1.7 | 40.1 | 38.1 | 32.4 | 5.0 | 23.2 | 4.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|